Amari M. Sockwell

Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner

A. Maitra, R. Kalluri, T. Heffernan, 2023, bioRxiv.

Antigen-presenting type-I conventional dendritic cells facilitate curative checkpoint blockade immunotherapy in pancreatic cancer

R. Kalluri, Huamin Wang, S. Shalapour, 2023, bioRxiv.

Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells.

R. DePinho, A. Maitra, R. Kalluri, 2023, Developmental cell.

KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells.

A. Maitra, R. Kalluri, T. Heffernan, 2023, Cancer cell.

Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer

Bingrui Li, Allison M. Dyevoich, S. Watowich, 2024, Science.